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Dengue is an emerging mosquito-borne viral infection with an estimated 2.5 billion 
people being at risk. The virus is found in tropical and subtropical areas around the 
globe and is transmitted by the main vector Aedes aegypti. According to WHO there 
are an estimated 50-100 million infections every year worldwide with an estimated 
500,000 cases being hospitalized annually. Currently there is no treatment available, 
thus there is an urgent need for discovering new drugs. 
 
The dengue NS3 serine protease is a promising target for new drugs since it is 
involved in viral polyprotein processing together with NS2B and thus important for 
viral replication. Crystal structures of NS2B-NS3pro bound to a peptide inhibitor 
recently revealed a pocket located at the opposite side of the protein from the active 
site. Residues from both NS2B and NS3 are lining the pocket, which is larger than the 
active site. Conservation in West Nile virus structures suggests functional importance. 
Based on these findings this study aims to characterize the NS2B-NS3 protease with 
its large allosteric pocket in more depth. Mutagenesis studies of different residues 
lining the pocket should help to understand the functional role of the pocket as a 
whole, as well as the impact on function for single residues in viral replication. The 
findings could further be used in drug development to specifically target residues that 
are crucial for viral replication. 
 
Mutagenesis studies of selected residues to alanine resulted in impaired or abolished 
protease activity for most of the mutants. The five mutants V078, W089, T118, G124 
and N152 were completely inactive. Mutants M084 and I165 were barely active 
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compared to WT. Only mutant Q167 showed slightly higher activity than WT. 
Furthermore protease activity could be restored for two selected mutants in additional 
conservative mutagenesis studies. The hydroxyl group in the threonine of position 
118 seems to be the main factor affecting protease activity since introduction of a 
serine lead to restorage of activity by 60%. For mutant M084 the introduction of a 
phenylalanine restored activity in a similar range than mutant T118, suggesting that 
hydrophobicity to be a main factor influencing activity. In general in vitro studies on 
viral replication were able to confirm results obtained from protease activity assays. 
In particular, protease activity could surprisingly not be restored for mutants N152D 
and I165L, even though the introduced amino acids differ only slightly from the WT 
residue. This suggests that those two residues are especially important for protease 
function. 
 
Overall, the results obtained from this study helped to identify residues within the 
allosteric pocket that are crucial for protease activity and viral replication. The pocket 
is therefore an attractive target and could potentially be targeted for the design of 
antiviral compounds. 
List of Tables 	  
viii	  
LIST OF TABLES 
Table 3.1  Mutated residues and codon usage in E. coli genes .............................44 
 
Table 3.2  Mutant protease activities compared to WT.........................................50 
 
Table 3.3  Kinetic parameters for DENV-3 NS2B-NS3 mutants and WT............52 
 
Table 3.4  Mutated residues and codon usage in E. coli genes .............................53 
 
Table 3.5  Mutant protease activities compared to WT.........................................54 
 
Table 3.6  Kinetic parameters for DENV-3 NS2B-NS3 mutants and WT............57 
 
















List of Figures 	  
ix	  
LIST OF FIGURES 
Figure 1.1  Flavivirus classification..........................................................................2 
 
Figure 1.2  Distribution of dengue infection according to the World Health 
Organization in 2010 ..............................................................................4 
 
Figure 1.3  WHO dengue classification scheme (1997) ...........................................6 
 
Figure 1.4  Updated classification scheme for dengue according to WHO (2009) ..7 
 
Figure 1.5  Schematic representation of Flavivirus life cycle ................................13 
 
Figure 2.1  Vector pGEX6P1..................................................................................32 
 
Figure 2.2  pACYC-NGC shutter B used to generate infectious clone ..................35 
 
Figure 2.3  pACYC-NGC infectious clone.............................................................36 
 
Figure 3.1  Structure of DENV-3 protease adopting the closed conformation.......41 
 
Figure 3.2  NS3-NS2B construct used for mutagenesis .........................................44 
 
Figure 3.3  Sequencing chromatogram...................................................................45 
 
Figure 3.4  Alignment of amino acid sequences for DENV 1-4 NS2B (A) and 
NS3pro (B) ...........................................................................................45 
 
Figure 3.5  Overexpression of mutated NS3-NS2B protein attached to a GST tag 
..............................................................................................................46 
 
Figure 3.6  Typical chromatograms after GST trap (left) and GST removal (right)
..............................................................................................................47	  
	  
Figure 3.7  Typical gel pictures of the different protein purification steps ............48 
	  
Figure 3.8  Schematic diagram of the principle of the AMC assay........................49	  
	  
Figure 3.9  Substrate dilutions plotted against fluorescence signal and analysed by 
non-linear regression fitted by the Michaelis-Menten equation...........51 
 
Figure 3.10  Activities of mutants compared to WT ................................................54 
 
Figure 3.11  Activities of mutants compared to WT ................................................55	  
 
Figure 3.12  Substrate dilutions plotted against fluorescence signal and analysed by 
non-linear regression fitted by the Michaelis-Menten equation...........55 
 
Figure 3.13  0.8% agarose gel to check for linearization (A) and RNA quality (B) 
..............................................................................................................58	  
List of Figures 	  
x	  
Figure 3.14  Viral replication in vitro of DENV-2 wildtype infectious clone..........61 
 
Figure 3.15  Viral replication in vitro of DENV-2 mutant T118S infectious clone 
..............................................................................................................62 
 
Figure 3.16  Viral replication in vitro of DENV-2 mutant T118A infectious clone 
..............................................................................................................63  
 
Figure 3.17  Viral replication in vitro of DENV-2 mutant I165A infectious clone
  ..............................................................................................................64 
 
Figure 4.1 Chemical structure of methionine (left) and phenylalanine (right) 
including their molecular weight..........................................................70 
 
Figure 4.2  Chemical structure of threonine (left) and serine (right) including their 
molecular weight ..................................................................................71 
 
Figure 4.3  Chemical structure of asparagine (left) and aspartic acid (right) 
including their molecular weight..........................................................72 
 
Figure 4.4  Chemical structure of isoleucine (left) and leucine (right) including 













List of Symbols 	  
xi	  
LIST OF SYMBOLS 
Aa   Amino Acid 
ADE   Antibody Dependent Enhancement 
AMC   7-Amino-4-Methylcoumarin 
Amp   Ampicillin 
BHK   Baby Hamster Kidney 
C   Capsid 
cDNA   Complementary DNA 
CHAPS  3-{(3-Cholamidopropyl)dimethyl-Ammonio}-1-
Propanesulfonate 
DAPI  4',6-Diamidino-2-Phenylindole 
DC  Dendritic Cell 
DC-SIGN  Dendritic-Cell-Specific ICAM-Grabbing Non-Integrin 
DENV   Dengue Virus  
DHF   Dengue Hemorrhagic Fever 
DMEM   Dulbecco’s Modified Eagle Medium 
DMSO  Dimethylsulfoxide 
dsRNA  Double-Stranded RNA 
DSS   Dengue Shock Syndrome 
E   Envelope  
EDTA   Ethylenediaminetetra Acetic Acid 
ER   Endoplasmic Reticulum 
FBS   Fetal Bovine Serum 
FBS   Fragment Based Screening 
Gly-Arg-Arg-AMC Gly-­‐Arg-­‐Arg-­‐7-­‐Amino-­‐4-­‐Methylcoumarin	  
List of Symbols 	  
xii	  
GRP-­‐78/BiP	   	   Glucose-­‐Regulating	  Protein	  78 
GST   Glutathione-S-Transferase 
HCV   Hepatitis C Virus 
HTS   High Throughput Screening 
ICAM   Intercellular Adhesion Molecule 
IFA   Immunofluorescence Assay 
IPTG   Isopropyl-β-D-Thiogalactopyranoside 
IVT   In Vitro Transcription 
JEV   Japanese Encephalitis Virus 
Kb   Kilobase 
kDA   Kilo Dalton 
LB   Luria Bertani 
MW   Molecular Weight 
NCR   Non Coding Region 
NGC   New Guinea C 
NITD   Novartis Institute for Tropical Diseases 
NS   Non Structural 
NS3hel  NS3 Helicase  
NS3pro  NS3 Protease  
O/N   Overnight 
ORF   Open Reading Frame 
PBS   Phosphate Buffered Saline 
PBST   PBS + 0.05% Tween 
PCR   Polymerase Chain Reaction 
prM   pre-membrane 
List of Symbols 	  
xiii	  
PS   Penicillin Streptomycin 
p.t.   Post Transfection 
RF   Replicative Form 
RC   Replication Complex 
RdRp   RNA Dependent RNA Polymerase 
Rpm   Rotations per Minute 
RT    Room Temperature 
SDM   Site Directed Mutagenesis 
SDS-PAGE  Sodium Dodecyl Sulfate-polyacrylamide Gel Electrophoresis 
STAT   Signal Transducer and Activator of Transcription 
TBEV   Tick-borne Encephalitis Virus 
TGN   Trans Golgi Network 
Tris   Tris(hydroxymethyl)aminomethane 
UTR   Untranslated Region 
WHO   World Health Organization 
WNV   West Nile Virus 
WT   Wildtype 
































Chapter 1 Introduction 	  
2	  
Chapter 1 Introduction 
 
1.1 Phylogeny of Dengue Virus 
 
Dengue virus (DENV) belongs to the family of Flaviviridae, which is a large family 
of viruses consisting of three genera; Flavivirus, Pestivirus and Hepacivirus. DENV is 
one of over 70 members of the genus Flavivirus causing severe disease and mortality 
in both humans and animals (Gubler et al., 2007). Flaviviruses are clustered into three 
different groups according to their mode of transmission, which can either be tick-
borne, mosquito-borne or unknown (Figure 1.1). DENV, yellow fever virus (YFV), 
Japanese encephalitis virus (JEV), tick-borne encephalitis virus (TBEV) and West 
Nile virus (WNV) are the most important pathogens amongst the flaviviruses that 
affect humans (Kuno et al., 1998; Mukhopadhyay et al., 2005). 
 
 
Figure 1.1 Flavivirus classification. The dendrogram shows the relationship of a 
selection of flavivirus members. Clades and clusters are based on molecular 
phylogenetics, whereas serological criteria are used to subdivide the viruses into 
antigenic complexes (Mukhopadhyay et al., 2005). 
1.2 Epidemiology 
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1.2.1 Epidemiology of Flaviviruses 
 
Some of the most important emerging as well as resurging diseases worldwide can be 
allocated to the genus of the mosquito-borne flaviviruses (Mackenzie et al., 2004). 
Emerging diseases are diseases characterized by a rapid increase in incidence or 
geographic spread of newly introduced or previously existing diseases in a population 
(Morse, 1995). Genomic sequence analyses have been used to understand origin, 
evolution and spread of flaviviruses. It has been suggested that they have evolved 
from an ancestral virus in Africa within the past 10’000 years. It is thought that 3’000 
years ago the tick-borne lineage evolved followed by the mosquito-borne lineage. 
YFV, from where the genus and the family got their names, is believed to have been 
carried from West Africa into the Americas during the slave trade in the 17th and 18th 
centuries. DENV on the other hand has spread globally in the 18th and 19th centuries 
with expanding shipping industry and trading. Additionally DENV transmission 
dynamics and epidemiology were shaped dramatically during and following World 
War II in South East Asia resulting in geographical spread of the disease and the 
vector. The factors contributing to emergence and resurgence of mosquito-borne 
viruses are complex and not well understood. However human activities like 
urbanization, transportation or changes in land use have clearly accounted strongly for 
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1.2.2 Epidemiology of Dengue Virus 
 
According to the World Health Organization (WHO) over 40% of the world’s 
population, or 2.5 billion people, live in areas of transmission and hence are at risk of 
getting dengue. Only nine countries were known to have severe dengue epidemics 
before 1970 and dengue is now endemic in more than 100 countries across the globe. 
The disease is present in many parts of the tropics and subtropics in Africa, the 
Americas, South-East Asia, the Western Pacific as well as the Eastern Mediterranean. 
An estimated 50-100 million dengue infections occur worldwide annually with 
500’000 severe cases every year being hospitalized and 2.5% deaths of those affected 
(Mackenzie et al., 2004).  
 
 
Figure 1.2. Distribution of dengue infection according to the World Health 
Organization in 2010. Highlighted in orange are the areas and countries where 
dengue has been reported. The January and July isotherms illustrate the areas at risk.  
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DENV circulates as four serotypes (DENV 1-4) and is mainly transmitted by 
mosquitoes Aedes aegypti and Aedes albopictus. It accounts for the highest disease 
and mortality rates amongst flaviviruses (Gubler, 1998). The four serotypes are 
closely related and share around 65% identity in their genome, which makes diagnosis 
difficult since they cross-react extensively in serological tests (Guzman et al., 2010). 
Although they are closely related, infection with one serotype only provides lifelong 
immunity for that specific serotype, but does not provide cross-protective immunity 
against another serotype (Mackenzie et al., 2004). In contrast, subsequent infection 
with another serotype has been reported to be a risk factor for developing Dengue 
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1.3 Clinical Manifestations 
 
A mosquito bite infected with DENV can lead to a wide range of clinical 
manifestations after an incubation period of 3-14 days (average 4-7 days). Infection 
can be asymptomatic or cause mild febrile illness, classical dengue fever, severe or 
sometimes even fatal hemorrhagic disease (World Health Organization Geneva 1997; 
Figure 1.3).  
 
Figure 1.3. WHO dengue classification scheme (1997). 
 
 
1.3.1 Dengue Fever (DF) 
 
Classical DF affects mainly older children and adults, resulting in a flu-like febrile 
illness accompanied by two or more manifestations like fever, frontal headache, body 
aches, joint pains, weakness, nausea and vomiting. DF is self-limiting and rarely fatal. 
Fever usually lasts 2 to 7 days and the virus is cleared from the blood in an average of 
5 days (Gubler, 1998; Rigau-Perez et al., 1998; WHO Geneva, 1997). 
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1.3.2 Dengue Hemorrhagic Fever (DHF) and Dengue Shock Syndrome (DSS) 
 
A small portion of DENV infections results in a more severe form of the disease 
called DHF and DSS. DHF is defined as meeting all of the following four criteria 
(WHO guidelines, 1997): fever or history of fever lasting 2-7 days, hemorrhagic 
tendency, low platelet count and plasma leakage. Distinguishing DHF from DF and 
other diseases found in tropical areas is difficult especially in the acute phase of 
illness and can also have an impact on treatment and hence on the fatality of the 
infection. Although DHF/ DSS is observed in all age groups, children are mainly 
affected. DSS refers to DHF where shock is present. DSS can be further classified 
into different severity grades of moderate or profound shock where pulse pressure is 
narrowed or not detectable respectively (Gubler, 1998; WHO Geneva, 1997). 
 
Since distinction between DF and DHF/DSS is difficult and crucial for disease 
outcome regarding treatment, the WHO classification scheme has recently been 
updated. Disease is classified into dengue with or without warning signs and severe 
disease. Warning signs include abdominal pain, mucosal bleed, persistent vomiting, 
clinical fluid accumulation, lethargy, restlessness, liver enlargement, increase in 
haematocrit and decrease in platelet count (WHO, 2009). 
 
 
Figure 1.4. Updated classification scheme for dengue according to WHO (2009). 
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1.4 Pathogenesis of Severe Dengue  
 
A variety of factors contributing to disease severity have been identified (Lei et al., 
2001). A number of studies have suggested prior encounter of dengue to be one of the 
most important risk factors for developing severe dengue (Dejnirattisai et al., 2010; 
Halstead, 1988; Gubler, 1998; Rothman, 2003). 
 
Antibody-dependant enhancement (ADE) has been proposed to play a key role in 
developing severe dengue. This was based on the fact that children who display 
severe manifestations of DHF/ DSS have already encountered a primary infection 
with a different serotype. In vitro studies have shown that preexisting antibodies to a 
previously exposed DENV serotype are not able to neutralize the new DENV 
serotype. In contrast they are able to enhance infection. Although epidemiological 
studies were able to confirm the association of secondary infection with disease 
severity, the underlying molecular mechanisms are still poorly understood. One 
hypothesized mechanism behind ADE is enhanced virus uptake into Fc-bearing cells, 
like monocytes or macrophages, promoted by opsonization through cross-reacting 
antibodies (Dejnirattisai et al., 2010; Halstead, 1988; Kliks et al., 1989; Lei et al., 
2001). In addition ADE has been shown to promote viral replication accompanied by 
upregulation of cytokines associated with DHF/ DSS resulting in a TH2-type response 
(Chareonsirisuthigul et al., 2007; Yang et al., 2001). 
 
An alternative hypothesis for pathogenesis of DHF/ DSS is the degree of virulence of 
different variants of DENV. The ability of viral replication in the host might 
contribute to the clinical outcome, since high viremia titer was associated with disease 
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severity. In addition it has been reported that the risk of DHF/ DSS is higher in 
secondary infections with DENV-2 compared to other serotypes (Rico-Hesse et al., 
1997; Rico-Hesse et al., 1998). 
 
Lei et al. suggested a new hypothesis of DENV immunopathogenesis in which both 
ADE and virus virulence can be explained. Dengue infection causes extensive 
immune activation leading to overproduction of cytokines as well as inability of the 
immune system to clear the virus that results in increased viral replication. Viral load 
becomes the key aspect linking both ADE and virus virulence (Lei et al., 2001). 
 
Although cross-reacting antibodies and virus virulence seem to play a key role in 
modulating the immune response and shaping disease outcome other factors most 
likely contribute to disease outcome as well. Additional risk factors that have been 
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1.5 Dengue Virus Life Cycle  
 
1.5.1 Structure of Dengue Virions 
 
Dengue virions are approximately 500 Å in diameter and contain a single positive-
strand RNA genome. The genome of around 10.8 kB is packaged by virus capsid 
protein and surrounded by a host-derived lipid bilayer. The virion surface incorporates 
two viral proteins, E (envelope) and M (membrane). The E glycoprotein mediates 
binding and fusion during virus entry, whereas the M glycoprotein is the remaining 
proteolytic fragment of precursor prM protein and produced during maturation 
(Figure 1.5 (a)). The RNA genome has an open reading frame that encodes a single 
polyprotein comprised of three structural and seven non-structural proteins (Figure 
1.5 (b)). The structural proteins – capsid, membrane and envelope – play an important 
role in viral assembly and viral maturation, whereas the non-structural proteins – NS1, 
NS2A, NS2B, NS3, NS4A, NS4B and NS5 – are essential for viral replication (Kuhn 
et al., 2002; Lindenbach et al., 2007; Mukhopadhyay et al., 2005). 
 
 
1.5.2 Viral Entry and Fusion 
 
DENV particles enter the cell via receptor-mediated endocytosis, triggered by host-
cell receptor and viral glycoprotein interactions (Figure 1.5 (1c)). In vitro studies have 
shown that DENV is able to infect a number of different human cells including 
dendritic cells, monocytes/ macrophages, B cells, T cells, endothelial cells, 
hepatocytes and neuronal cells. In vivo studies suggested that the main target cells of 
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DENV are cells of the mononuclear phagocyte lineage (monocytes, macrophages and 
DCs) (Clyde et al., 2006). Host-cell receptors interacting upon virus particle 
attachment include DC-SIGN (Navarro-Sanchez et al., 2003), GRP78/BiP 
(Jindadamrongwech et al., 2004) and CD14-associated molecules (Chen et al., 1999). 
 
Membrane fusion is mediated by the viral surface E protein and takes place in the 
endosome (Figure 1.5 (2c)). The E protein undergoes conformational changes to form 
trimers triggered by the acidic environment within the endosome that leads to fusion 
of the viral and the cell membrane (Figure 1.5 (3c)). The nucleocapsid is then released 
into the cytoplasm and replication of the RNA genome is initiated after dissociation of 




1.5.3 Viral Replication, Assembly and Release 
 
Upon release into the cytoplasm the positive-sense viral RNA is translated into a 
single polyprotein that is further cleaved co- and post-translationally by host and viral 
proteases into 10 proteins (Lindenbach and Rice, 2003). Virus assembly occurs on the 
surface of the endoplasmic reticulum (ER) (Figure 1.5 (6c)). Immature, non-infectious 
viral particles, that cannot induce host-cell fusion, are formed in the lumen of the ER 
and later released into the trans-Golgi network (TGN). Cleavage of the prM protein 
(Figure 1.5 (7c)), mediated by the host-cell protease furin in the TGN, creates mature 
and infectious particles that are later released at the cell surface via exocytosis 
(Mukhopadhyay et al., 2005). 
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It is thought that the genomic RNA forms a replication complex (RC) together with 
NS proteins and host proteins on cytoplasmic membranes (Lindenbach and Rice, 
2003; Westaway et al., 2003). Replication starts at the 3’ end and results in an 
intermediate double-stranded negative-sense RNA, called the replicative form (RF). 
The dsRNA RF is then converted into a replicative intermediate complex (RI) that 
serves as a template in order to synthesize more positive-strand genomic RNA 
(Khromykh and Westaway, 1997). NS5, containing the RNA dependent RNA 
polymerase (RdRp), is essential for the production of RFs (Ackermann and 
Padmanabhan, 2001; Tan et al., 1996), whereas conversion of RF to RI involves 
interaction of both NS5 and NS3 (Bartholomeusz and Wright, 1993; Kapoor et al., 
1995; Raviprakash et al., 1998). Other studies have shown colocalization of RCs with 
NS1, NS2A, NS2B and NS4A, suggesting a functional role in viral replication (Chu 
et al., 1992; Mackenzie et al., 1996; Mackenzie et al., 1998). 
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Figure 1.5. Schematic representation of Flavivirus life cycle. (a) Schematic 
representation of the virus particle. Immature virions contain prM and E as 
membrane-associated proteins. Upon maturation the prM protein is cleaved and the M 
protein stays attached to the surface. (b) Schematic representation of the genome 
organization. The positive-stranded RNA genome of approximately 11 kB comprises 
an ORF encoding three structural and seven non-structural proteins. The ORF is 
flanked by NCRs at both ends. (c) The virus life cycle can be divided into seven parts: 
(1) Attachment of the virus particle to the host cell membrane (2) Viral entry via 
receptor-mediated endocytosis (3) Fusion of viral and host cell membrane (4) 
Uncoating and release of viral RNA into cytoplasm (5) Translation and replication of 
viral genome (6) Assembly of viral particles (7) Exocytosis and release of mature 
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1.6 DENV Structural and Non-structural Proteins  
 
DENV is an enveloped virus containing a single-stranded positive-sense RNA 
genome of approximately 11 Kb in length. The genome encodes three structural 
proteins (pre-membrane, envelope and capsid) forming the viral particle and seven 
non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) required 
for viral replication, virion assembly and invasion (Kummerer and Rice, 2002; Liu et 
al., 2003; Rice et al., 1985). 
 
 
1.6.1 Capsid  
 
The capsid (C) protein is highly basic, approximately 11 kDa in size, and contains 
charged residues at its N- and C- termini. An internal short hydrophobic domain 
mediates membrane association (Boege et al., 1983; Khromykh and Westaway, 1997; 
Rice et al., 1985; Trent, 1977). Dimerization of the C protein, triggered by viral RNA, 
is essential for viral assembly (Kiermayr et al., 2004; Kummerer and Rice, 2002; 
Lopez et al., 2009; Ma et al., 2004). Although the C protein sequence homology 
within Flavivirus is low, the hydrophobic and hydrophilic regions are conserved 
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1.6.2 Pre-membrane  
 
The Pre-membrane (prM) protein is a precursor protein (~ 34 kDa) of the membrane 
(M) protein (~ 26 kDa) and is cleaved by the host protease furin in the TGN. Cleavage 
mediates maturation and is important for release of viral particles (Elshuber et al., 
2003). In addition prM is essential for proper folding and secretion of the envelope 
protein. Its association with prM protein prevents it from undergoing conformational 
changes that normally trigger fusogenic activity (Guirakhoo et al., 1991; Guirakhoo et 
al., 1992). After cleavage of prM, pr gets secreted, whereas the M protein stays 
attached to the mature virion. 
 
More recent studies have shown that recombinant E-prM complexes are immunogenic 
and protective in vaccines against several flaviviruses like JEV (Mason et al., 1991), 




1.6.3 Envelope  
 
The E protein (~ 53 kDa) is the major structural protein exposed at the surface of the 
virion. It plays a role in a number of processes including receptor binding, membrane 
fusion, virion assembly and is the major target for neutralizing antibodies (Chambers 
et al., 1990; Heinz, 1986). The E protein contains 12 cysteine residues, which form 
intramolecular disulfide bonds and are highly conserved within Flavivirus (Chambers 
et al., 1990; Mandl et al., 1989). In immature virions E is linked to prM and forms 
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heterodimers that protect it from premature acidification while they are transported 






NS1 (~ 46 kDa) is a highly conserved glycoprotein that is exported via the secretory 
pathway to the membrane, where it is either anchored or released as a soluble protein  
(Mackenzie et al., 1996; Mason, 1989; Schlesinger et al., 1990; Westaway et al., 
1997). NS1 contains 12 conserved cysteine residues, invariant glycosylation sites and 
some other regions of high sequence homology. In recent studies NS1 has been 
shown to associate with double-stranded RF suggesting a role in viral replication 
(Mackenzie et al., 1996; Westaway et al., 1997). In addition association with 
immature E protein in the ER most likely indicates a role in virion assembly and 





NS2A (~ 22 kDa) is one of four (NS2A, NS2B, NS4A, NS4B) small, hydrophobic 
proteins of the polyprotein. The hydrophobic regions are conserved in position but not 
sequence, suggesting membrane-association of these proteins (Chambers et al., 1990; 
Rice et al., 1986). The function has yet to be discovered. NS2A has been shown to 
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bind to NS3 and NS5 and localize to the RC, suggesting an involvement in viral 
replication (Mackenzie et al., 1998). 
1.6.6 NS2B 
 
NS2B is a small (~ 14 kDa) mebrane-associated protein, which is involved in 
polyprotein processing together with NS3. The conserved, hydrophilic region, 
spanning residues 49-95, is flanked by two hydrophobic domains. The hydrophobic 
domains enable membrane-association, whereas the hydrophilic portion interacts with 
NS3. Recent studies have shown, that the conserved 40 residue long hydrophilic 
portion is crucial for NS3 serine-protease activity. Disruption of NS2B-NS3 
interaction can abolish NS3 protease activity (Arias et al., 1993; Chambers et al., 
1991; Chambers et al., 1993; Falgout et al., 1991; Falgout et al., 1993; Leung et al., 
2001; Li et al., 1999; Li et al., 2005; Yusof et al., 2000). 
 
 
1.6.7 NS3  
 
NS3 (~ 68 kDa) is the second largest protein of the DENV genome and contains 
multiple functions crucial for viral propagation. Protease, helicase, NTPase as well as 
5’-terminal RNA triphosphatase activities are key features involved in viral 
polyprotein processing, genome replication and virus particle assembly (Chambers et 
al., 1990; Lindenbach et al., 2007). The RNA helicase is required for unwinding 
dsRNA during viral replication, whereas the NTPase is necessary to provide the 
energy for unwinding. The RTPase on the other hand is involved in capping of viral 
RNA. The NS3 protease is crucial for cleavage of the polyprotein together with NS2B 
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(Benarroch et al., 2004; Borowski et al., 2001; Chambers et al., 1993; Lescar et al., 
2008; Patkar and Kuhn, 2008; Wengler et al., 1991). 
 
1.6.7.1 NS3 Protease  
 
The first 180 aa at the N-terminal region of NS3 encode for the DENV NS3pro and 
are highly conserved among flaviviruses (Valle and Falgout, 1998). NS3pro itself is 
not active and also not stable unless it is bound to NS2B, which is required for 
catalytic activity (Li et al., 2005). A construct containing residues 49-95 of NS2B 
linked to residues 1-169 of NS3 via a Gly4-Ser-Gly4 linker has been described for 
WNV and DENV 1-4 in order to express soluble and active protease (Leung et al., 
2001; Li et al., 2005). A number of studies to characterize the NS2B-NS3 protease as 
well as to screen new potent protease inhibitors have been conducted based on this 
construct (Noble et al., 2011; Salaemae et al., 2010; Yin et al., 2006a,b). A recent 
study in addition has revealed the ligand-bound crystal structure of the NS2B-NS3 
protease closed conformation. When NS2B wraps around NS3 a cavity larger than the 
active site is formed on its opposite side. Residues of both NS2B and NS3 are lining 
this newly identified pocket, which could be a potential new drug target (Noble et al., 
2011).  
 
The DENV protease is a trypsin-like serine protease containing a His-Asp-Ser 
catalytic triad (H51, D75 and S135) that is essential for protease activity since 
mutations in those residues abolish enzymatic activity (Bazan and Fletterick, 1989; 
Speight et al., 1988). Trypsin-like serine proteases are able to cleave peptide bonds 
following a positive charged amino acid like arginine and lysine. The hydroxyl-group 
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of the serine (Ser) acts as a nucleophile, attacking the carbon of the substrate’s 
carbonyl-group. Histidine (His) firstly acts as a base and assists in forming a 
tetrahedral intermediate, which is stabilized by the hydrogen bond to aspartic acid 
(Asp). The now positively charged His then acts as a general acid leading to the 
formation of an acylenzyme intermediate. This is later attacked by water yielding a 
second tetrahedral intermediate and finally leading to cleavage of the peptide bond 
(Hedstrom, 2002). 
 
NS2B-NS3 protease mediates cleavage of the polyprotein between NS2A/ NS2B, 
NS2B/ NS3, NS3/ NS4A, NS4A/ NS4B and NS4B/ NS5. In addition it is also 
responsible for cleavage within C, NS2A and NS3 (Lindenbach et al., 2007). 
 
 
1.6.8 NS4A and NS4B 
 
NS4A (~ 16 kDa) and NS4B (~ 27 kDa) are two small, hydrophobic proteins with yet 
unknown functions (Lindenbach et al., 2007). The C-terminus of NS4A acts as a 
signal sequence for NS4B to translocate to the ER lumen (Lin et al., 1993; Preugschat 
et al., 1991). In addition NS4A colocalizes with the RF, suggesting a functional role 
in viral replication (Mackenzie et al., 1998). 
 
Colocalization of the transmembrane protein NS4B with NS3 and viral dsRNA in 
cytoplasmic ER-derived membrane structures suggests a role in viral replication 
(Miller et al., 2006). In addition NS4B is able to dissociate NS3 from ssRNA 
(Umareddy et al., 2006). NS4B has also been shown to interfere with interferon by 
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NS5 is the largest (~ 104 kDa) protein and is also highly conserved. NS5 contains a S-
adenosylmethionine dependent methyltransferase (MTase) at its N-terminus, which is 
involved in 5’ capping of the viral genome (Dong et al., 2008; Koonin and Dolja, 
1993). The C-terminus encodes for a RNA dependent RNA polymerase (RdRp), 
which is essential for viral replication (Rawlinson et al., 2006; Tan et al., 1996). In 
addition NS5 harbours two nuclear localization signals at residues 320 to 405, which 
are likely to play an important role in transportation of NS5 into the nucleus (Brooks 
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1.7 Control of Dengue 
 
1.7.1 Treatment of Dengue 
 
Although primary DENV infections do not need treatment in most cases, a lot of 
patients have to be hospitalized in hyperendemic countries, which is associated with a 
high financial burden. And yet there is no treatment or vaccine available to control 
dengue. Currently the only way to tackle dengue is to prevent transmission by 
controlling its vector, Aedes aegypti (Mackenzie et al., 2004). 
 
Current treatment for DF and DHF/ DSS are non-specific and basically treat the 
symptoms. Patients with DF require rest, oral fluids to prevent dehydration and 
antipyretics for high fever. Acetaminophens but not salicylates are recommended to 
reduce risk of bleeding complications. DHF treatment involves a combination of 
immediate diagnosis, monitoring hemorrhagic complications and supportive care 
(Rigau-Perez et al., 1998). 
 
1.7.2 Vector Control 
 
Given the fact that there is no treatment for dengue, vector control is the only means 
to prevent DF and DHF/ DSS. The most effective way to control mosquito 
populations is to reduce larval habitats by removing or cleaning water-holding 
containers where mosquitoes can breed. Successful eradication programs have been 
implemented in the American region in the 1950’s and 1960’s. Unfortunately the 
program was disbanded after reduced disease burden and has lead to re-infestation of 
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the mosquito vector. Increased awareness of dengue as a public health issue, together 
with implementation of sustainable vector control strategies are therefore likely to 




The fact that infection with one serotype of DENV confers life-long immunity against 
that serotype indicates the potential for developing a vaccine against DENV. In 
addition vaccines for closely related flaviviruses like YFV, JEV and TBEV have been 
marketed already. However, to date there are no vaccines against dengue on the 
market, although vaccine development was initiated as early as the 1940’s (Coller et 
al., 2011). According to the Pediatric Dengue Vaccine Initiative, a promising vaccine 
candidate might be marketed as early as 2015. 
 
The occurrence of four different serotypes represents a huge challenge in developing 
vaccines. Especially challenging, with regards to the ADE hypothesis, is the concern 
of immune enhancement triggered by vaccination leading to more severe disease upon 
a secondary encounter of the pathogen. The lack of an adequate animal model makes 
it additionally complex to test vaccine candidates (Bente and Rico-Hesse, 2006). 
 
Nevertheless a promising vaccine candidate is currently undergoing phase III clinical 
studies. This live attenuated tetravalent vaccine is based on the YFV vaccine strain 
with additional substitutions of dengue virus membrane and envelope protein genes 
(Guirakhoo et al., 2006; Whitehorn and Farrar, 2010). 
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1.7.4 Antiviral Therapy 
 
Approximately 40% of the world’s population is at risk of getting dengue. It is 
therefore essential to develop therapeutics that inhibit DENV, since there are no 
antivirals available on the market. However development of drugs against dengue are 
complicated. Drugs need to be safe, inexpensive and effective. High survival rates and 
often mild disease outcomes are factors that counteract attempts to develop 
treatments. Another issue hindering the development of new treatments is the lack of 
appropriate animal disease models (Bente and Rico-Hesse, 2006). Replication in 
animals other than humans and mosquitoes is impaired and the clinical pathology of 
the disease is often not reflected (Julander et al., 2011). 
 
Research on dengue virus biology has revealed a variety of viral and host proteins that 
could potentially be targeted by antiviral therapeutics. Whereas host factors are 
difficult to target, due to potential toxicity and side effects, a few viral proteins are 
promising. 
 
Both structural as well as non-structural proteins of the DENV polyprotein present 
interesting targets. A drug targeting the viral E protein, involved in viral-host-
membrane fusion, could inhibit viral entry (Heinz et al., 2012). Therapeutic antibodies 
could be used to attack structural proteins that are found on the surface, however ADE 
of dengue infection has to be avoided (Rajamanonmani et al., 2009). NS3 and NS5 on 
the other hand are involved in viral replication and could therefore be targeted to 
reduce viremia in patients (Lescar et al., 2008; Noble et al., 2011). In addition, a lot of 
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these proteins are highly conserved among flaviviruses inferring potential application 
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1.8 Aims of the Thesis 
 
The emergence and resurgence of dengue in tropical and subtropical areas together 
with the lack of available antiviral therapeutics or vaccines urges the need to develop 
new treatment methods. Understanding the basic molecular mechanisms that underlie 
viral replication are essential in finding new drug targets as well as obtaining 
information for rational drug design.  
 
The work in this study focuses on the viral NS3-NS2B protease that has progressively 
gained attention as a potential antiviral target. The crystal structure of NS3-NS2B 
protease, involved in polyprotein processing and crucial for viral replication, has 
recently been solved. Crystal structures have revealed an allosteric pocket lined by 
residues of both NS2B and NS3. The goal of this study is to assess the functional 
importance of this pocket by mutating selected residues lining the pocket. Enzymatic 
activities of the recombinant mutant protein will be measured and a selection of 
mutants will be used to study viral replication in vitro. Together these studies should 
help characterize the allosteric pocket and its potential role in viral replication and 
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2.1.1 Cloning Primers 
 




























































Mutated residues are highlighted in red 
 
 
2.1.2 DNA Sequencing Primers 
 
Primer Name    DNA sequence 
 
SEQ_D2NS3_FOR  CCATCATGGGCGGACGTTAAGAAAGACC 
SEQ_D2NS3_REV  GGTCCATGATGGTCAATTTTCTCTTTCG 
 
SEQ_D2-3’UTR_FOR  GGGCAAAGAACATCCAAACAGC 
 
pGEX_FOR   GGGCTGGCAAGCCACGTTTGGTG 
PGEX_REV   CCGGGAGCTGCATGTGTCAGAGG 
 








































Primary Antibody Species Clonal Company 
Anti-NS3 rabbit polyclonal in house 
Anti-E 4G2 mouse monoclonal in house  
 
Secondary Antibody Name Catalogue Nr. Company 
Goat anti-rabbit IgG, 
fluorescin conjugated 
TRTC T6778 Sigma-Aldrich 
Goat anti-mouse IgG, 
fluorescin conjugated 
FITC F0257 Sigma 
 




2.2.1 Generating DENV-3 Protease Mutants  
 
Vector pGEX6P1 (GE Healthcare, Figure 2.1) containing the residues 49 to 96 of 
NS2B DENV serotype 3 (strain S221/03) connected to residues 1-182 of NS3 DENV-
3 by a G4SG4 linker was used to generate protease mutants (V078A, M084A, 
W089A, T118A, G124A, N152A, I165A, Q167A kindly provided by Lee, Le Tian; 
NITD as well as M084F, T118S, N152D, and I165L). Mutations were introduced 
using QuickChangeTM site-directed mutagenesis (SDM) with specific mutagenic 
primers. PCR conditions were as follows: 95°C for 30 sec; followed by 18 cycles of 
95°C for 50 sec, 60°C for 50 sec and 68°C for 9 min; and finished with 68°C for 7 
min) (detailed protocol in section appendix: PCR mix and cleaning up of PCR 
product). The PCR products were then transformed into XL1Blue competent cells (in 
house) and spread on LB agar plates containing 100 µg / ml ampicillin (detailed 
protocol of bacterial transformation in section appendix). Clones were isolated and 
purified using the QIAprep Spin Miniprep Kit to further be verified by DNA 
sequencing (AITbiotech, Singapore).  
 
 
2.2.2 Expression and Purification of DENV-3 Protease Mutants  
 
Protease mutant constructs and the wildtype (WT) construct were transformed into 
chemically competent BL21 DE3 cells (in house), spread on Luria Bertani (LB) plates 
containing 100 µg / ml ampicillin and grown overnight (O/N) at 37°C. One individual 
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colony per plate was picked and inoculated into 20 ml of LB broth containing 100 µg 
/ ml ampicillin and incubated at 37°C O/N shaking at 220 rpm. 5 ml of the O/N 
culture was then inoculated into 500 ml LB broth containing ampicillin using a 2l 
flask. The cultures were grown at 37°C shaking at 220 rpm until the OD595 had 
reached 0.6-0.8 and then cooled down to 4°C for 10 min. Protein expression was then 
induced by adding 0.5 mM Isopropyl-β-D-thiogalactopyranoside (IPTG) and kept 
shaking at 160 rpm at 16°C O/N. The cultures were harvested by centrifugation at 
6’000 rpm at 4°C for 10 min and the cell pellet was then resuspended in GST binding 
buffer (20 mM TRIS-HCl pH 7.5, 300 mM NaCl, 1 mM EDTA) before being lysed 
using a sonicator (50% intensity, 10 min, pulse 2 sec on and 5 sec off) (detailed 
protocol in section appendix: growing cells and expression of proteins, protein 
purification). The lysate was later centrifuged at 20’000 rpm for 1 hour at 4°C and the 
supernatant, containing the recombinant protein attached to a glutathione S-
transferase (GST) tag at its N-terminus, loaded onto a GSTrapTM FF 5 ml column (GE 
Healthcare) for further purification with GST binding buffer and GST elution buffer 
(40mM TRIS-HCL pH 7.5, 300 mM NaCl, 1 mM EDTA and 2 mM gluthathione). 
Fractions were analyzed by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) to select for cleavage using Prescission protease (GE 
Healthcare) incubating at 4°C O/N. After being purified through the GST column 
again, cleavage was confirmed by SDS-PAGE. In a last step the proteins were 
concentrated using a Vivaspin concentrator (Sartorius) and then loaded onto a 
HiLoadTM 26/60 SuperdexTM 200 column that was equilibrated with gel filtration 
buffer (20 mM TRIS-HCl pH 7.5, 300 mM NaCl). Samples were picked according to 
SDS-PAGE gel analysis and concentrated and quantified using a NanoDrop® 
Spectrophotometer ND-1000m by measuring the absorbance at 280 nm.  






Figure 2.1. Vector pGEX6P1. Schematic representation of vector containing the 
DENV-3 NS2B-NS3 protease construct as well as an ampicillin resistance cassette 
(AmpR) to select for mutants that successfully have taken up the plasmid. In addition 
the vector carries a LacI site to induce protein expression as well as a GST tag used 
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2.2.3 Dengue NS3 Protease Activity Assay 
 
The enzymatic activity of the NS2B-NS3 recombinant protease mutants was assessed 
using a fluorogenic peptide substrate Gly-Arg-Arg-7-amino-4-methylcoumarin (Gly-
Arg-Arg-AMC) and an automated fluorescence plate reader (Tecan). The assay 
principle is explained in chapter 3, section 3.1.3. The substrate was diluted in 50 mM 
TRIS-HCl, pH 8.5 + 20% (v/v) glycerol and the recombinant protease mutants were 
diluted in 50 mM TRIS-HCl, pH 8.5 + 20% (v/v) glycerol + 2.5 mM CHAPS. The 
enzyme assay was performed in a final volume of 20 µl per well of a Corning Costar 
black 96-well plate. Both substrate and enzymes were incubated at 37° C for 10 min 
prior to putting them together and measuring the fluorescence. Measurement was also 
done at 37° C at an excitation wavelength of 385 nM and an emission wavelength of 
465 nM. Substrate concentrations were in the range of 30 µM to 750 µM whereas 
protease concentrations were in the range of 0.1 µM to 0.5 µM. Fluorescence values 
in rfu/min were plotted vs. substrate concentration and Michealis-Menten kinetics 
were obtained using Prism software by performing non-linear regression. Various 
dilutions and sets of measurement were conducted. Duplicates for each measurement 
were performed and average and standard deviations were calculated. 
 
 
2.2.4 Construction of Genome-length DENV-2 Mutant cDNA   
 
pACYC-NGC SacII/XhoI (shutter B, kindly provided by Xie, Xuping; NITD) 
containing the structural proteins C, prM and E as well as the non-structural proteins 
NS1, NS2A, NS2B and NS3 of DENV-2 (Figure 2.2) was used to generate a new set 
Chapter 2 Materials and Methods 	  
34	  
of protease mutants using QuickChangeTM SDM and the respective primers as 
previously described. The PCR product was then transformed into XL1 Blue 
competent cells and positive clones were isolated and DNA sequencing was used to 
verify the mutations (AITbiotech, Singapore). 
 
The positive mutant constructs and the WT construct (DENV-2 infectious clone 
Figure 2.3; kindly provided by Xie, Xuping; NITD) were digested with Xho-1 and 
Nhe-1 for 3 h at 37°C (detailed protocol in section appendix: digestion mix). Samples 
were run on a 0.8% agarose gel and the respective bands excised and further purified 
using a QIAquick spin column (detailed protocol in section appendix: QIAquick gel 
extraction kit protocol). The vector and the individual mutants were then ligated O/N 
at 16°C using T4 DNA ligase to generate genome-length DENV-2 infectious clones 
(detailed protocol in section appendix: ligation mix). The ligation mixture was then 
transformed into Top10 competent cells (Invitrogen) and positive clones further 
analyzed by DNA sequencing. 
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Figure 2.2. pACYC-NGC shutter B used to generate infectious clone. Vector 
containing the structural proteins C, prM and E as well as the non-structural proteins 
NS1, NS2A, NS2B and NS3. The restriction sites Xho I and Nhe I were used to cut 
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Figure 2.3 pACYC-NGC infectious clone. WT construct containing the whole 
genome of DENV-2 and the restriction sites Xho I and Nhe I to introduce the shutter 
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2.2.5 In Vitro Transcription of Genome-length DENV-2 Infectious Clone 
 
In order to be in vitro transcribed, the genome-length DENV-2 constructs were 
linearized using ClaI restriction enzyme incubated at 37°C for 2 h (detailed protocol 
in section appendix: linearization). Cleavage was then confirmed by running a 0.8% 
agarose gel and the linear plasmid further purified by ethanol precipitation. In vitro 
transcription was performed using the mMessage mMachine® Kit (Ambion) at 37°C 
for 2 h followed by a DNase I treatment for 15 min (detailed protocol in section 
appendix: in vitro transcription). The mixtures were then cleaned by phenol-
chloroform and precipitated using ethanol. 
 
 
2.2.6 Culturing and Passaging of BHK21 Cells 
 
A vial containing frozen baby hamster kidney cells (BHK21-US) in 
Dimethylsulfoxide (DMSO, Sigma) and Fetal Bovine Serum (FBS, Thermo 
Scientific) was dissolved in 10 ml fresh Dulbecco’s Modified Eagle Medium 
(DMEM) containing 10% FBS, 1% Penicillin-Streptomycin (PS, Gibco) and 5% 
glutamine. The cells were incubated at 37°C and 5% CO2 in a culture flask. Cells 
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2.2.7 RNA Transfection and Immunofluorescence Assay (IFA) 
 
Cells were harvested and counted in order to get a suspension of 1 x 107/ ml BHK21-
US cells in PBS. Work using living virus was done in the virus room under Biosafety 
conditions 2. 800 µl of that cell suspension and 10 µg of the in vitro transcribed RNA 
were then transferred into a 0.4 cm gap sterile Gene Pulser Electroporation cuvette 
(Bio-Rad) and pulsed 3 times at 850 V and 25 µF (3 second intervals) using Gene 
Pulser XcellTM Electroporation System (Bio-Rad). After a recovery time of 10 min at 
RT the cells were resuspended in a final volume of 25 ml DMEM with 10% FCS and 
5% glutamine. 500 µl, 250 µl, 150 µl and 100 µl (respectively for the different days 
post transfection) of the cell suspension were then seeded into 4-well plates with 
coverslips and incubated at 37°C. Samples were then fixed and stained on day 1, day 
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Chapter 3 Results 
 
3.1 The Allosteric Pocket in the Dengue Protease  
 
3.1.1 Generating DENV-3 NS2B-NS3 Mutants 
 
Correct polyprotein processing is crucial for viral replication and is mediated by a 
combination of host proteases and the viral NS2B-NS3 protease (Cahour et al., 1992; 
Falgout et al., 1991). In order to be fully active the NS3 protease, encoded by residues 
1-182 of the N-terminal non-structural protein 3, requires NS2B for activity. In 
addition subsequent findings suggested that a 47 amino acid long hydrophilic portion 
of the non-structural protein 2B is sufficient for its activity (Erbel et al., 2006). 
Crystal structures have been reported recently for the DENV-3 protease-peptide 
complex that revealed a cavity larger than the active site. This pocket is formed when 
NS2B wraps around NS3 and is located at the opposite side of the protein from the 
active site (Chappell et al., 2008; Noble et al., 2011; Figure 3.1). 
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(C)  
Figure 3.1. Structure of DENV-3 protease adopting the closed conformation. (A) 
Surface view of the DENV-3 protease shown in green and residues selected for 
mutagenesis highlighted in magenta. (B) Reverse view of A. (C) Structure of DENV-
3 protease in its closed conformation shown in cartoon representation. NS3 is 
coloured in green, whereas NS2B is shown in blue. Residues selected for mutagenesis 
are represented as sticks and highlighted in red for residues on NS2B and magenta for 
residues on NS3. The cartoons were generated using PyMOL software and the 
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A construct containing residues 49 to 96 of DENV-3 NS2B linked by Gly4SerGly4 
(G4SG4) to residues 1-182 of DENV-3 NS3 (Figure 3.2) was used to generate 
protease mutants in order to assess the importance of this newly identified pocket. 
Since the crystallized structure from the recent study was DENV-3, this serotype was 
also used in my study. 
 
A subset of residues that are lining the pocket formed by NS2B-NS3 were picked to 
introduce an amino acid change to alanine using SDM. Replacing the residues with an 
alanine removes the functional side chain of the original amino acid. Since alanine is 
the simplest amino acid, carrying only a non-reactive methyl group at the α-carbon, it 
is seldom directly involved in enzyme catalysis. Suggesting that, residues mutated to 
alanine, which show impaired or abolished enzymatic activity are of functional 
importance for the protease. The primers for SDM containing the mutation site were 
designed according to a codon usage table for E. coli. I tried to achieve a change of as 
few nucleotides as possible in the codon of interest itself as well as avoiding the use 
of very rare codons in order to reduce mismatches to make the PCR reaction simpler 
(Table 3.1). The mutant constructs were then analysed by sequencing. Figure 3.3 
shows a typical sequencing result where mutagenesis could be confirmed. 
 
Figure 3.4 shows the sequence alignment for NS2B and NS3 for all four DENV 
serotypes. The residues selected for mutagenesis studies are highlighted with asterisk. 
Residues lining the newly identified pocket were picked based on conservation among 
the serotypes. They are highly conserved for the four serotypes. In addition, NS3 
shows a high level of sequence conservation within the Flavivirus genus, implying 
functional importance of this region. NS2B on the other hand is less conserved among 
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flavivirus. However NS2B of different flaviviruses contain structural similarities like 
hydrophobic domains, with a potential to span membranes (Chambers et al., 1990).  
 
 
Figure 3.2 NS3-NS2B construct used for mutagenesis. Schematic representation of 









Residue Codon switch Codon usage frequency1 
NS2B-DENV-3 
 
	    
Val078Ala GTT to GCT 1.8 







Trp089Ala TGG to GCG 3.2 
Thr118Ala ACT to GCT 1.8 
Gly124Ala  GGA to GCA 2.1 




ATA to GCA 
CAA to GCA 
2.1 
2.1 
1 average frequency this codon is used per 100 Codons 
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Figure 3.3. Sequencing chromatogram. Typical sequencing result with mutated 









Figure 3.4. Alignment of amino acid sequences for DENV 1-4 NS2B (A) and 
NS3pro (B). Residues selected for mutagenesis studies are highlighted with asteriks. 
Yellow shading indicates 100% identity, whereas blue indicates conservative regions 
with green shading for amino acids with similar properties. 
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3.1.2 Expression and Purification of DENV-3 NS2B-NS3 Recombinant Protein 
 
Mutant constructs were transformed into competent E. coli cells, cultured and protein 
expression was induced by IPTG. Overexpression was confirmed by SDS-PAGE 
(Figure 3.5). Proteins were purified using a GST column in a three-step process. 
Figure 3.6 shows selected graphs and Figure 3.7 shows selected gels of the different 
purification steps.  
 
 
Figure 3.5. Overexpression of mutated NS3-NS2B protein attached to a GST tag. 
Overexpression of NS2B-NS3 protease mutants expressed in E. coli was confirmed 
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Figure 3.7. Typical gel pictures of the different protein purification steps. SDS-
PAGE after GST trap (A), GST removal (B) and Gel filtration (C). Fractions 
containing the protein attached to GST are collected (Frac 8-12, A) and prescission 
protease is used to cleave the tag. The flow through (B) containing the cleaved protein 




3.1.3 Assessing the Enzymatic Activity of DENV-3 NS2B-NS3 Protease Mutants 
 
In order to assess the enzymatic activity for the different protease mutants an assay 
was performed using a fluorogenic peptide substrate Gly-Arg-Arg-AMC. The peptide 
bound to the fluorophore (AMC) is preventing the fluorescence of AMC. Cleavage 
mediated by the protease releases AMC and a strong fluorescence signal can be 
measured (Yusof et al., 2000; Figure 3.8). Based on that principle the performance of 






Figure 3.8. Schematic diagram of the principle of the AMC assay. Peptide bound 
to the AMC substrate is only weakly fluorescent. As soon as the protease cleaves to 





A variety of different enzyme as well as substrate concentrations were used to assess 
the protease activity. Enzyme concentrations were in the range of 0.1 to 0.5 µM, 
whereas substrate dilutions were performed in the range of 30 to 750 µM. Activities 
relative to WT are summarised in table 3.2. Mutant Q167A showed a slight increase 
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of activity compared to WT. Residual activity could be seen with mutants I165A (3% 
compared to WT) and M084A (11% compared to WT). 
 
In order to obtain kinetic parameters, substrate dilutions were performed and 
fluorescence signals were plotted against substrate concentrations. The graphs were 
then analyzed by non-linear regression using GraphPad Prism 5 software and fitted to 
the Michealis-Menten equation. Figure 3.9 shows two graphs obtained after analysis. 
Measurements were conducted in duplicates and average values and the 


















Table 3.2. Mutant protease activities compared to WT. Mutants were compared at 
0.25 µM enzyme concentration and at 150 µM substrate concentration. Measurements 









































    






Figure 3.9. Substrate dilutions plotted against fluorescence signal and analysed 
by non-linear regression fitted by the Michaelis-Menten equation. A shows WT 
and B shows mutant T118A that showed no activity. Mean values were plotted and 
error bars reflect standard deviations obtained from duplicate measurements. 
 
 
Table 3.3 shows the different kinetic parameters that were obtained from the 
measurements of the enzymatic assay for the mutants and WT. Since the values have 
not been compared and adjusted to standard concentrations of AMC, they are quoted 
in arbitrary units of RFU. They still represent true kinetic values and can be used to 
compare the mutants. 
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As already shown in table 3.2 only three mutants showed activity. Mutants V087A, 
W089A, T118A, G124A, N152A showed no activity at all and values for vmax are 
extremely small and therefore calculations of kinetic parameters meaningless. Even 
with increasing enzyme and substrate concentrations enzymatic activity could not be 
rescued. The same is true for mutant I165A that showed only little activity (Table 
3.2). The kcat and the kcat/KM as well as vmax are reduced for M084A, whereas the KM 
is increased. The kcat for Q167A as well as the kcat/KM are highly increased with an 
almost two-fold and three-fold increase respectively compared to WT. The KM on the 
other hand is reduced. The main difference between the active mutants lies in the 
Michaelis-Menten constant (KM), therefore suggesting that mutant M084A reduces 
the affinity and Q167A increases the affinity for the substrate. 
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3.1.4 Additional Mutagenesis Studies with Selected Residues 
 
From the previously picked residues four were chosen to conduct some additional 
mutagenesis studies. The mutations as well as the codons that were used in the 
primers are summarized in Table 3.4.  
 
 
Residue Codon switch Codon usage frequency1 
NS2B-DENV-3 
 
	    







Thr118Ser ACT to TCT 1.1 
Asn152Asp AAT to GAT 3.3 
Ile165Leu ATA to CTA 0.3 
1 average frequency this codon is used per 100 Codons 
Table 3.4. Mutated residues and codon usage in E. coli genes 
 
 
Table 3.5 summarizes the activities in percentages compared to WT. Mutant N152D 
is completely inactive, likewise the mutant N152A. Mutant I165L shows residual 
activity in a similar range to mutant I165A. However mutants M084F as well as 
T118S show activities that are only slightly reduced compared to WT. This is a 
striking contrast to when the same residues are mutated to alanine (Table 3.2). Figure 
3.10 compares the same four mutants with WT graphically including the data for the 
corresponding alanine mutants. For an overall comparison Figure 3.11 shows the data 
for all mutants that showed activity compared to the WT. 
 
 













Table 3.5. Mutant protease activities compared to WT. Mutants were compared at 
an enzyme concentration of 0.25 µM and a substrate concentration of 150 µM. 









Figure 3.10. Activities of mutants compared to WT. Graph shows the four mutants 
that were selected for further mutagenesis studies as well as their corresponding 
alanine mutants. T118A, N152A and N152D are also included in the graph although 
they did not show activity. Measurements were done in duplicates and the mean value 
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Figure 3.11. Activities of mutants compared to WT. Graph shows all active 
mutants from the two sets of mutagenesis studies. Measurements were done in 












Figure 3.12. Substrate dilutions plotted against fluorescence signal and analysed 
by non-linear regression fitted by the Michaelis-Menten equation. Mutant T118S 
(A) exhibited increased activity compared to the alanine mutant, whereas I165L (C) 
only showed a little and N152D (B) no activity. Mean values were plotted and error 
bars reflect standard deviations obtained from duplicate measurements. 
 
Table 3.6 shows the different kinetic parameters that were obtained from the 
measurements of the enzymatic assay for the four selected mutants and WT. No 
activity could be measured for mutant N152D, which is also reflected in the kinetic 
parameters. Vmax is again extremely small similar to mutant N152A and therefore 
calculations for additional kinetic parameters have been excluded. The same is true 
for mutant I165L, which exhibited little activity (Table 3.5). The kinetic parameters 
for both mutants M084F and T118S are similar (Table 3.5). They have an increased 
kcat and a significantly higher kcat/KM as compared to the inactive mutants. The KM 
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values for the active mutants and WT are in a similar range, suggesting that the 
mutations do not have an influence on substrate affinity. However the differences for 
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3.1.5 Assessing Viral Replication of Selected Mutants In Vitro 
 
To examine the relevance of the biochemical results obtained in section 3.1.3 and 
3.1.4 a DENV-2 infectious clone, carrying mutations on NS2B-NS3 protease, was 
generated and transfected into BHK21 cells. In contrast to the biochemical assays 
previously conducted, DENV-2 was used, simply because this serotype was available 
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at our institute. The idea was to monitor viral replication in vitro using 
immunofluorescence. The mutations as well as the codons that were used in the 
primers to generate the infectious clone are summarized in Table 3.7. A smaller 
shutter vector containing approximately half of the viral genome (8’934 bp, Figure 
2.2) was used to first introduce the mutation, since it is easier to genetically 
manipulate this smaller vector. In a second step, the shutter containing the desired 
mutation was cleaved and ligated into the whole WT infectious clone (14’369 bp, 
Figure 2.3). Sequencing was used to check for the 3’ UTR as well as the introduction 
of the correct mutation. In order to be in vitro transcribed, the cDNA plasmid was 
linearized using a restriction enzyme (ClaI). Linearization was confirmed by 0.8% 
agarose gel electrophoresis (Figure 3.13 A). After in vitro transcription the RNA 
quality was checked by agarose gel electrophoresis (Figure 3.13 B) before BHK21 
cells could be transfected. 
 







Thr118Ala ACC to GCA 2.1 
Thr118Ser ACC to AGC 1.5 
Ile165Ala ATA to GCA 2.1 
1 average frequency this codon is used per 100 Codons 
Table 3.7. Mutated residues and codon usage in E. coli genes 
 







Figure 3.13. 0.8% agarose gel to check for linearization (A) and RNA quality (B). 
Gel confirmed that mutant infectious clones were linearized by ClaI restriction 
enzyme (A). RNA purity after IVT was checked by an agarose gel (B). 
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Viral replication was monitored for 4 days post transfection (p.t.) and samples were 
stained for the envelope protein (anti-E 4G2) and NS3 (anti-NS3). Expression of both 
NS3 and the envelope protein can be clearly seen in the WT clone, where expression 
peaked at day 3 and 4 p.t. respectively (Figure 3.14). For mutant T118S NS3 
expression is slower and fewer cells are IFA-positive compared to WT with peaked 
expression at day 4. The staining for the envelope protein is not as strong as for NS3. 
Nevertheless substantial expression can be seen on day 4 p.t (Figure 3.15). Mutant 
T118A shows less expression of NS3 as well as envelope protein compared to both 
WT and T118S. Only a few cells express both proteins and the majority of cells are 
IFA-negative even at day 4 p.t. (Figure 3.16). Samples for mutant I165A were IFA-
negative for both NS3 as well as the envelope protein (Figure 3.17). 
 
These findings are consistent with the data from the enzyme activity assay and show 
that mutations to alanine impair NS3 activity, whereas the specific mutation of 
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Chapter 4 Discussion  
 
An estimated 50 to 100 million infections are caused every year by one of the four 
DENV serotypes (Guzman et al., 2010). And yet there are no clinically approved 
vaccines or therapeutics. It is therefore essential to understand the basic principles 
behind DENV infection in order to get new potential targets leading to vaccines or 
antiviral therapeutics.  
 
Viral proteases have shown to be a potential target. Two protease inhibitors that are 
acting against the viral protease of HCV, belonging to the genus Flavivirus, have been 
approved recently (Chen and Njoroge, 2009). Others are still in various stages of 
clinical trials (Soriano et al., 2011).  
 
The DENV protease domain, comprising the first ~ 170 amino acids of NS3, shares 
high sequence homology with various members of the genus Flavivirus (Valle and 
Falgout, 1998). The serine protease is crucial for viral polyprotein processing and 
depends on association with a hydrophilic portion of the NS2B protein for activity 
(Erbel et al., 2006). Together with host proteases, the viral protease is essential for 
viral replication and therefore a putative target against DENV infection (Chambers et 
al., 1990). Recent findings have revealed a pocket larger than the active site that is 
formed, when NS3-NS2B adopts the closed conformation. Residues from both NS3 as 
well as NS2B are lining that pocket (Noble et al., 2011). Furthermore conservation of 
the pocket in the WNV protease structure suggests that it is functionally important 
(Aleshin et al., 2007; Erbel et al., 2006).  
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Based on these findings mutagenesis studies were conducted on selected residues 
lining the pocket in order to get a better understanding of how this newly identified 
pocket influences protease activity, and whether it can be targeted by direct-acting 
antivirals. 
 
In the first part of our study eight residues of DENV-3 NS2B-NS3 that line this 
pocket, were selected, mutated to alanine and tested for enzymatic activity (Table 
3.1). Based on these results, four of these residues were picked for further 
mutagenesis studies (Table 3.4). Finally, an infectious clone of DENV-2 was used to 
assess viral replication in vitro for three of the selected mutants (Table 3.7). 
 
 
4.1. Alanine Mutagenesis Studies 
 
Alanine substitutions in the selected residues of DENV-3 NS2B-NS3pro indeed had 
marked effects on enzymatic activities. Five Mutants were completely inactive, 
whereas activity for two mutants was substantially decreased compared to WT. 
However one mutant showed slightly increased activity compared to WT. Since the 
values obtained for vmax for the inactive mutants were extremely small, kinetic 
parameters were only calculated for the two active mutants and WT. Substantial 
differences could be seen in KM, a measure that is related to the substrate binding 
affinity. It is more than two-fold increased for mutant M084 whereas reduced by half 
for Q167 compared to WT. Differences for vmax were not as striking. The same is true 
for kcat values, since calculations directly depend on vmax (Table 3.3). Together this 
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suggests that mutations in those two residues have an impact on the binding affinity 
rather than on the maximal rate and the turnover number kcat.  
 
Salaemae et al. have previously conducted a similar study where they mutated 
selected residues of DENV-2 NS3 to alanine. They were able to show that alanine 
substitution had a vital effect on substrate affinity for all selected mutants with one 
exception. All mutants showed increased KM values whereas one mutant had a 
slightly higher substrate affinity compared to WT. Of interest in relation to my study 
are their results for residues N152 and I165. Of all the mutants, where activity was 
detectable, those showed the highest KM values and smallest values for kcat, indicating 
a dramatic impairment on enzymatic activity (Salaemae et al., 2010). This is 
overlapping with our findings where activities for residues N152 and I165 were also 
dramatically reduced. Yet our values have not been adjusted to standard 
concentrations of AMC as compared to Salaemae’s study and hence individual values 
cannot be compared directly. In addition DENV-3 was used in my study, whereas the 
previous study used DENV-2 protease, which is more active in vitro and hence the 
kinetics cannot be directly compared anyway. However, these results suggest that 
these two residues are of high importance for the function of the NS3 protease and 
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4.2. Additional Mutagenesis Studies 
 
Residues M084 located on NS2B as well as T118, N152 and I165 located on NS3 





Mutating the methionine at position 84 to an alanine in NS2B had already an 
extensive impact on protease function. Activity was ten-fold reduced compared to WT 
indicating the residue to be of importance for enzymatic activity (Table 3.2). Ligand-
bound crystal structures of NS2B-NS3 have recently revealed that NS2B actually 
wraps around NS3 forming a β-hairpin in the closed conformation. Where backbone 
carbonyls of M084, as well as of G82, interact with specific substrate side chains and 
thereby stabilize the β-hairpin structure (Noble et al., 2011). In addition to that, 
DENV-4 (Figure 3.4) as well as WNV proteases carry a phenylalanine instead of the 
methionine at the same position. We therefore decided to generate another mutant 
containing a phenylalanine at residue 84. The protease function could be partially 
rescued by addition of an aromatic side chain instead of a methyl group and lead to a 
five-fold increase in activity compared to M084A (Figure 4.1). However mutant 
M084F still showed impaired cleavage efficiency compared to WT, despite both 
residues having long hydrophobic side chains.  
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Figure 4.1. Chemical structure of methionine (left) and phenylalanine (right) 
including their molecular weight. 
 
 
Comparing the obtained kinetic parameters to WT substantial differences for vmax and 
therefore kcat as well can be seen. However the KM differs only slightly from WT. 
Suggesting that the mutation has an impact on the maximal rate and the catalytic 
efficiency rather than on the binding affinity. This agrees with the findings of Noble 
et al. where residue M084 was suggested to be stabilizing the β-hairpin of NS2B 
wrapping around NS3 (Noble et al., 2011), therefore facilitating cleavage, once 
substrate has bound, by keeping NS2B in close proximity to NS3. Additionally 
methionine and phenylalanine are both hydrophobic, whereas alanine is smaller and 
less hydrophobic. Hydrophobic interactions are important for stabilizing the protein’s 










The alanine mutation at position 118 in NS3 had a remarkable impact on cleavage 
activity of the protease. No activity could be detected. The idea of introducing a serine 
instead of an alanine at that position was to see if activity could be rescued, by a more 
conservative change for threonine to serine. Essentiallly the serine was able to restore 
activity to more than 60% compared to WT. As seen for mutant M084F, the 
Michaelis-Menten constant for mutant T118S was also only slightly affected. 
However the maximal rate and the kcat showed a five-fold decrease in contrast to WT. 
Serine and threonine are the two only amino acids carrying an aliphatic hydroxyl 
group. They can basically be seen as the hydroxylated version of alanine and valine. 
Adding a hydroxyl group renders them more hydrophilic as well as more reactive 
(Figure 4.2).  
 
Figure 4.2. Chemical structure of threonine (left) and serine (right) including 
their molecular weight. 
 
 
Recovery of activity by introducing a serine instead of an alanine therefore suggests 
that the hydroxyl group is the main factor influencing protease activity.  
 




N152 was shown to be important for protease activity in a recent study on WNV as 
well as on DENV-2. Activity of the N152A mutant was completely abolished in 
WNV, whereas in DENV-2 a substantial 60-fold decrease in catalytic efficiency 
compared to WT could be measured (Chappell et al., 2005; Salaemae et al., 2010). 
There was no detectable activity in my study, which is consistent with the earlier 
findings. In order to identify the determinant responsible for abolished activity we 
wanted to introduce a subtle change and see if activity could be rescued. An aspartic 
acid was introduced instead of an asparagine basically replacing the amide group by a 
carboxylate (Figure 4.3). 
 
 
Figure 4.3. Chemical structure of asparagine (left) and aspartic acid (right) 
including their molecular weight. 
 
 
Similar to mutant N152A, only residual activity could be detected for N152D. 
Residue N152 is part of the allosteric pocket and its side chain presumably interacts 
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with the substrate side chain via hydrogen bonding as suggested recently (Erbel et al., 
2006). Asparagine can function both as a hydrogen bond donor as well as an acceptor. 
The amino group in particular serves as a donor enabling it to potentially form a 
specific contact with the substrate. Aspartic acid on the other hand is only able to 
serve as a hydrogen bond acceptor at physiological pH. Therefore suggesting that the 
hydrogen donor function is essential for protease function, since activity could not be 





Mutation of I165 to alanine resulted in a dramatic increase in KM in a recent study 
suggesting an important role in substrate binding (Salaemae et al., 2010). Removing 
the bulky side chain lead to a dramatic decline in activity likewise in my study. By 
replacing the alanine by a leucine I wanted to find out whether activity was dependent 
on the size and shape of the side chain. Isoleucine and leucine share the same 
chemical formula and properties. The only difference between the two amino acids is 
the orientation and shape of the carbon side chain (Figure 4.4). 
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Figure 4.4. Chemical structure of isoleucine (left) and leucine (right) including 
their molecular weight. 
 
Although a two-fold increase in activity could be detected compared to mutant I165A, 
activity is still extremely low compared to WT. This again agrees with the suggestion 
of Salaemae et al. for residue I165 being involved in substrate binding rather than 
catalysis. The hydrophobicity of the amino acid does not determine activity. Instead 
the shape of the side chain within the protein seems to be a major factor influencing 
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4.3 Viral Replication In Vitro 
 
In order to assess the relevance of the biochemical results from the mutagenesis 
studies, viral replication was monitored in vitro. RNA from DENV-2 whole-genome 
infectious clones of mutants T118A, T118S, I165A and WT were transfected into 
BHK21 cells and immunofluorescence staining was done for days 1-4 post 
transfection. Cells were stained for NS3 protein as well as the envelope protein. DAPI 
was used to confirm the localization of NS3 and envelope protein with respect to the 
nucleus within the infected cell.  
 
NS3 staining was chosen since we were mutating the NS3 protease and wanted to 
know whether NS3 was actually present in infected cells. In addition, since the 
protease is mediating polyprotein processing by cleavage, occurrence of envelope 
protein indicates NS3 protease activity.  
 
Surprisingly NS3 as well as envelope staining were detectable for mutant T118A. 
Although only few cells were IFA-positive and replication seemed to be delayed this 
result contradicts the AMC assay outcome, where no activity was detectable. A 
possible explanation for the observed discrepancy could be due to the fact that two 
different serotypes of DENV were used in the biochemical assay and the IFA. DENV-
2 is in general more active than DENV-3 in vitro, explaining the partial activity of 
DENV-2 T118A infectious clone in the IFA. Another possible reason for the observed 
differences could also be due to assay sensitivity. Low activity may be sufficient for 
in vitro replication. Mutant T118S on the other hand agreed with the biochemical 
results. Viral replication was slower as well as fewer cells were infected compared to 
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WT. Nevertheless a substantial number of cells were IFA-positive. In general a clear 
difference can be observed between the two mutants, suggesting that the main driving 
factor for protease function is the hydroxyl group. 
 
For mutant I165A, which hardly showed enzyme activity in vitro, no IFA-positive 
cells could be detected. Viral replication was totally abolished suggesting that even 
though the protease was partially active, the virus was not able to propagate within the 
cell. This again strengthens the important role for NS3 protease in viral replication, 
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4.4 Impact of Findings on Drug Discovery 
 
I was able to show that apart from the active site an even larger pocket formed within 
the NS2B-NS3 protease has an impact on enzymatic activity. This could be due to an 
allosteric mechanism affecting the active site and hence affecting protease function. 
Key residues and features of amino acids have been identified that had marked effect 
on protease function. Therefore this pocket could serve as a potential target for an 
antiviral drug against dengue. In order to screen for compounds that specifically bind 
to this pocket and not the active site, fragment-based screening (FBS) would be a 
novel useful tool, as opposed to other conventional screening methods like high 
throughput screening (HTS). FBS compounds have usually a much lower molecular 
weight and often only bind weakly to the target. Detection of hits is therefore 
challenging and relies on use of specific techniques like nuclear magnetic resonance 
(NMR) or X-ray crystallography. FBS in general leads to higher hit rates and 
compared to HTS also fewer compounds have to be screened. But since the affinity 
towards the target is usually lower it can be difficult to optimize leads in order to get a 
lead that meets all the necessary requirements. One possible way to increase affinity is 
for example to combine multiple low affinity hits that bind to different sites of the 
target molecule and link these fragments together. In relation to the NS2B-
NS3protease, structural approaches can now be used to identify molecules that 
specifically bind to the identified key residues in the allosteric pocket and that later 
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4.5 Conclusion and Outlook 
 
The DENV NS2B-NS3 protease has progressively gained interest in the last years, 
especially as a potential target for antiviral therapeutics. A number of studies have 
been conducted to characterize the two-component protease from a biochemical point 
of view as well as from the structural point of view. Studies in the past have mainly 
focussed on the active site of the DENV protease. However, recent studies have 
revealed another pocket larger than the active site, which is conserved among the 
DENV serotypes and likely to be of importance for the protease function.  
 
This study was for the first time able to identify key residues in the DENV NS2B-
NS3 protease allosteric pocket, that are important for protease function. In addition, 
conservative mutagenesis studies revealed key features of a selected subset of 
identified residues, crucial for protease activity. Recombinant DENV-3 protease was 
used to biochemically assess the functional importance of the allosteric site. In vitro 
replication studies, with a DENV-2 infectious clone, were later used to in confirm the 
biochemical results obtained with DENV-3.  
 
Taken together these findings are especially valuable for drug discovery. The 
identified key residues are highly conserved within DENV 1-4 and our results for 
both DENV-3 and DENV-2 were overlapping. A protease inhibitor targeting the 
allosteric site could therefore potentially be used for more than one serotype. 
Fragment-based screening, as a novel approach, could be useful in order to design 
inhibitors targeting not only one specific binding site, but combining several binding 
sites in close proximity. It would be interesting to further extend our experiments to  
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other DENV serotypes and include additional conserved mutagenesis studies for 
additional key residues. This could give us a complete picture of the functional 
importance of the allosteric pocket within the four serotypes. In addition one could 
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6.1 Additional protocols 
Bacterial transformation 
1. add 1-10 µl of the plasmid DNA to one tube of competent cells 
2. incubate on ice for 30 min 
3. heat shock the cells for 30-60 sec in the waterbath at 42°C (not shaking) 
4. transfer the tube on ice and incubate for another 2 min 
5. add 300 µl of nutrient broth (LB), 100 µl for SDM 
6. cap the tube tightly and shake it for 30-60 min at 37°C shaking at 220 rpm, place on 
ice 
7. spread the transformation onto a LB plate containing 100 µg/ml ampicillin, incubate 
for 10 min at RT and then invert the plate and place it into the 37°C incubator O/N 
 
Cleaning up of PCR product 
 
1. add 1/10 of the whole volume of 4M NaCl to PCR product 
2. add 2.5 times of the total volume of 100% ice cold ethanol to the mixture 
3. incubate on ice for 15 min 
4. centrifuge at 4°C at maximum speed for 15 min  
5. remove liquid and air dry the tube 
6. resuspsend in 3-10 µl water 
 
Growing cells and expression of proteins 
 
1. pick an individual colony from the LB plate grown O/N and start a 20 ml LB culture 
containing 100 mg/ml amp O/N at 37°C shaking at 220 rpm 
2. inoculate 5 ml of the O/N culture into 500 ml LBAmp in a 2 l flask (aeration!) 
3. shake the flasks at 37°C and 160 rpm for 2-3 hours and regularly check the OD 
4. as soon as the OD has reached 0.6-0.8 cool down the cultures to 4°C for 10 min 
5. add IPTG to 0.5 mM and incubate shaking at 30°C and 160 rpm for 4 hours 
(alternatively incubate at 16°C O/N) 
6. centrifuge the culture for 10 min at 6000 rpm and discard the supernatant 




1. sonicate the sample at 50% intensity, pulse 2 sec on and 5 sec off for 10 min 
2. centrifuge cell lysate after sonication at 20'000 rpm for 45-60 min at 4°C 
3. filter lysate with a 0.20 µm filter 
4. inject lysate into FPLC machine using a GST column 








QIAquick gel extraction kit protocol 
 
1. weigh the gel slice in a colorless tube and add 3 volumes of buffer QG to the tube 
(100 mg = 100 µl) 
2. incubate the tube containing the gel slice and buffer QG in a waterbath at 50°C until 
the slice has completely dissolved (make sure that the color of the mixture is still 
yellow) 
3. add 1 gel volume of isopropanol to the sample mix and place it into a QIAquick spin 
column 
4. spin the column for 1 min and then discard the flow through 
5. add another 500 µl buffer QG to the spin column and centrifuge for 1 min 
6. to wash add another 750 µl of buffer PE + ethanol to the column, let it stand for 5 min 
and centrifuge for 1 min 
7. repeat step 6 
8. discard the flow through and centrifuge for another 1 min 
9. place the column into a new microcentrifuge 
10. add 35 µl of water to center of the column to elute DNA, let it stand for 1 min and 




T4 DNA Ligase         1 µl  
T4 DNA ligase buffer (10x)        1.5 
µl  
Plasmid1          3-6 
µl  
Insert1           3-6 
µl  
Add water to a final volume of       15 µl
  
1The ratio between plasmid and insert has to be 1:3-5. My plasmid is about 3 times bigger than the inserts hence I 





10x buffer NEB2         5 µl
  
10x BSA          5 µl
  
DNA           2 µg
  
Nhe-I           1 µl
  
Xho-I           1 µl
  








In vitro transcription 
cDNA (linear)         2 µg 
2 x dNTPs/ Cap        10 µl 
10x buffer          2 µl 
Enzyme mix         2 µl 
Add water to a final volume of      20 µl  
 
Linearization 
10x buffer NEB        10 µl 
10x BSA         10 µl 
ClaI          10 µl 
DNA          10 µg 




Nuclease-free water        37.5 µl  
Quik Solution (DMSO)       3 µl  
10x Buffer with MgSO4       5 µl 
dNTP mix, 10 mM each       1 µl 
primer mix (10mM each)       1.5 µl 
DNA template (20 ng/µl)       1 µl 
Polymerase (2.5/ µl)        1 µl 
 
 
 
